Kolexia
Sobhani Iradj Gastro-entérologie
Sobhani Iradj
Gastro-entérologie
Hôpital Henri Mondor
Créteil, France
137 Activités
11 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Adénocarcinome Tumeurs du côlon Dysbiose Lymphomes Lymphome B de la zone marginale Tumeurs de l'estomac Urgences Carcinomes

Collaborateurs

Voir plus
Amiot Aurelien
Amiot Aurelien
Hôpital Henri Mondor, Créteil, France
Gagniere Charlotte
Gagniere Charlotte
Hôpital Henri Mondor, Créteil, France
De Angelis Nicola
De Angelis Nicola
Hôpital Beaujon, Clichy, France
Levy Michael
Levy Michael
Hôpital Henri Mondor, Créteil, France

Industries

Voir plus
Biocodex
9 collaboration(s)
Dernière en 2023
Ipsen
5 collaboration(s)
Dernière en 2022
Galapagos SASU
3 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
The colibactin-producing alters the tumor microenvironment to immunosuppressive lipid overload facilitating colorectal cancer progression and chemoresistance.
Gut microbes   28 février 2024
Loss of symbiotic and increase of virulent bacteria through microbial networks in Lynch syndrome colon carcinogenesis.
Frontiers in oncology   05 février 2024
Gastric microbiota in patients with gastric MALT lymphoma according to Helicobacter pylori infection.
Clinics and research in hepatology and gastroenterology   18 novembre 2023
Focal loss of mural stratification as a radiological predictor for small bowel adenocarcinoma in Crohn's disease.
Clinics and research in hepatology and gastroenterology   13 novembre 2023
, an oral pathobiont associated with colorectal cancer, epigenetically reprograms human colonocytes.
Gut microbes   16 octobre 2023
OPERA: perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogel.
European journal of endocrinology   01 septembre 2023
BEVANEC: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Essai Clinique (Hospices Civils de Lyon)   18 avril 2023
Long-Term Results of Endoscopic Metal Stenting for Biliary Anastomotic Stricture after Liver Transplantation.
Journal of clinical medicine   11 février 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
The Lancet. Oncology   02 février 2023
Oral microbiota in obstructive sleep apnea patients: a systematic review.
Sleep & breathing = Schlaf & Atmung   07 octobre 2022